Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.

Dr. Victoria Werth explains how diagnosing BP can pose many difficulties in patients due to the variation of symptoms and symptom severity. Dr. Werth also discusses what burden and challenges BP patients might expect as a result.
Join Prof. Sietze Reitsma for an insightful presentation that will delve into identifying and leveraging key characteristics to optimize patient management and treatment outcomes.

Dr Kwatra poses the question: How do we assess disease modification in PN, and can treating early stop tissue damage and worsening of systemic diseases associated with PN?
Meet Fernando. Journey through his clinical profile, applying guideline-based checklists to reach a consensus regarding his diagnosis.
Dr. Elena Netchiporouk discusses the chronic nature of CSU at EADV 2025.
Professor Matthias Augustin highlights the high prevalence of both atopic and non-atopic comorbidities in patients with PN, including increased risks of cardiovascular events and all-cause mortality.

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.
Learn about the role of type 2 inflammation in the burden and pathophysiology of mucus plugging in severe asthma

Join Dr. Culton as she discusses the unmet treatment needs in bullous pemphigoid, and the importance of understanding pathophysiology in disease management.

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.